ReviewJournal of clinical neurology (Seoul, Korea)2015
Oral disease-modifying therapies for multiple sclerosis.
Review in Journal of clinical neurology (Seoul, Korea), 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed.
- Nucleoside-Analog Reverse-Transcriptase Inhibitors (NRTIs) Against Multiple Sclerosis: Comprehensive Review on a Possible Novel Therapeutic Approach.Neurology international · 2026Review
- Drug Repurposing: A Leading Strategy for New Threats and Targets.ACS pharmacology & translational science · 2024Review
- Multiple Sclerosis in a Patient With Neurogenic Locus Notch Homolog Protein 3 Mutation.Journal of clinical neurology (Seoul, Korea) · 2023Article
- The efficacy and safety of oral disease-modifying therapies for relapsing-remitting multiple sclerosis: A systematic review.Current journal of neurology · 2020Article
- Monoclonal Antibody Therapies for Multiple Sclerosis and Neuromyelitis Optica Spectrum Disorder.Journal of clinical neurology (Seoul, Korea) · 2020Review
- Therapeutic Potential of Ponesimod Alone and in Combination with Dimethyl Fumarate in Experimental Models of Multiple Sclerosis.Innovations in clinical neuroscience · 2019Article
- A comprehensive review on the treatment approaches of multiple sclerosis: currently and in the future.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2019Review
- Management Strategies to Facilitate Optimal Outcomes for Patients Treated with Delayed-release Dimethyl Fumarate.Drug safety · 2018Review
- Persistence to oral disease-modifying therapies in multiple sclerosis patients.Journal of neurology · 2017Article
- Cladribine to treat disease exacerbation after fingolimod discontinuation in progressive multiple sclerosis.Annals of clinical and translational neurology · 2017Article
- Dimethyl fumarate treatment of relapsing-remitting multiple sclerosis influences B-cell subsets.Neurology(R) neuroimmunology & neuroinflammation · 2016Article
- Review
- Sphingosine-1-phosphate inhibits IL-1-induced expression of C-C motif ligand 5 via c-Fos-dependent suppression of IFN-β amplification loop.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2015Article
- dNP2 is a blood-brain barrier-permeable peptide enabling ctCTLA-4 protein delivery to ameliorate experimental autoimmune encephalomyelitis.Nature communications · 2015Article
- Costs and quality of life by disability among people with multiple sclerosis: a register-based study in Sweden.Multiple sclerosis journal - experimental, translational and clinicalArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Classical multiple sclerosis (MS) treatments using first-line injectable drugs, although widely applied, remain a major concern in terms of therapeutic adherence and efficacy. New oral drugs recently approved for MS treatment represent significant advances in therapy. The oral route of administration clearly promotes patient satisfaction and increases therapeutic compliance. However, these drugs may also have safety and tolerability issues, and a thorough analysis of the risks and benefits is required. Three oral drugs have been approved by regulatory agencies for MS treatment: fingolimod, teriflunomide, and dimethyl fumarate. This article reviews the mechanisms of action, safety, and efficacy of these drugs and two other drugs that have yielded positive results in phase III trials: cladribine and laquinimod.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.